摘要
目的:探究注射用尤瑞克林治疗脑梗死的效果及其对侧支循环评分、CXC型趋化因子配体16(CXCL16)及可溶性CD40配体(CD40L)的影响。方法:选取建湖县人民医院2018年4月-2021年2月收治的82例脑梗死患者,采取随机数字表分为对照组和观察组,各41例,除了有3例中途出院及2例要求退出研究外,最终有77例患者完成了研究,对照组38例,观察组39例。两组均给予常规治疗,对照组给予丁苯酞氯化钠注射液静脉滴注治疗,观察组在对照组基础上加用注射用尤瑞克林治疗,两组均连续治疗2周。对比两组临床疗效、治疗前后NIHSS评分、外侧裂+脑凸面侧支系统评分(Maas评分)与大脑中动脉区域侧支系统评分(Tan评分),CXCL16、CD40L水平,同时观察并记录两组不良反应。结果:与对照组相比,观察组临床总有效率较高,差异有统计学意义(P<0.05);与对照组相比,观察组治疗后NIHSS评分较低、Maas评分及Tan评分较高,CXCL161及CD40L水平均较低,差异均有统计学意义(P<0.05)。两组不良反应发生率比较差异无统计学意义(P>0.05)。结论:注射用尤瑞克林治疗脑梗死可获得较好的临床效果,减轻对神经功能的损伤,避免再发脑梗死的发生,进一步促进血管内皮功能的恢复,且治疗期间无明显不良反应,安全性较高。
Objective:To explore the effect of Ureklin Kallidinogenase for Injection in the treatment of cerebral infarction and its influence on collateral circulation score,CXC chemokine ligand 16(CXCL16)and soluble CD40 ligand(CD40L).Method:A total of 82 patients with cerebral infarction admitted to Jianhu County People’s Hospital from April 2018 to February 2021 were selected and divided into the control group and the observation group by random number table,with 41 patients in each group.Except for 3 cases who were discharged midway and 2 cases who were required to withdraw from the study,there were finally 77 patients completed the study,38 cases in the control group and 39 cases in the observation group.Both groups were given conventional treatment.The control group was given intravenous infusion of Butylphthalide Sodium Chloride Injection treatment.The observation group was added to the Ureklin Kallidinogenase for Injection treatment on the basis of control group.Both groups were treated continuously for 2 weeks.The clinical efficacy,NIHSS score,sylvian fissure+convex surface collateral system score(Maas score)and the collateral system score of the middle cerebral artery(Tan score),CXCL161,CD40L levels before and after treatment were compared between the two groups.Adverse reactions in the two groups were observed and recorded.Result:Compared with the control group,the clinical total effective rate in the observation group was higher,and the difference was statistically significant(P<0.05).Compared with the control group,NIHSS score was lower,Maas score and Tan scores were higher,and CXCL16 and CD40L levels were lower in the observation group after treatment,and the differences were statistically significant(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion:The treatment of cerebral infarction with the Urekline Kallidinogenase for Injection can achieve better clinical effects,reduce the damage to nerve function,avoid the occurrence of recurrence of cerebral infarction,and further promote the recovery of vascular endothelial function,and there are no obvious adverse reactions during the treatment,with high safety.
作者
陈武
CHEN Wu(Jianhu County People’s Hospital,Jianhu 224700,China)
出处
《中外医学研究》
2022年第1期27-30,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
关键词
注射用尤瑞克林
丁苯酞氯化钠注射液
脑梗死
疗效
侧支循环
神经功能
内皮功能
不良反应
Ureklin Kallidinogenase for Injection
Butylphthalide Sodium Chloride Injection
Cerebral infarction
Curative effect
Collateral circulation
Nerve function
Endothelial function
Adverse reactions
